NASDAQ$FLGT
Fulgent Genetics Inc. · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Fulgent Genetics reported a 48% increase in revenue and a non-GAAP income for Q4 2019.
Fulgent Genetics announced its Q4 and Full Year 2019 financial results, with Q4 revenue reaching $8.4 million, a 48% increase year-over-year. The company reported a GAAP loss of $296,000, or $0.01 per share, and a non-GAAP income of $778,000, or $0.04 per share for the quarter.
- Revenue totaled $8.4 million, growing 48% year over year.
- Billable tests delivered totaled 13,977, growing 118% year over year.
- Gross Margin improved more than 5 percentage points year over year and cost per test improved approximately 40% year over year.
- Adjusted EBITDA was $1.1 million.
Headline financials
Revenue & EPS history
Fulgent · Revenue · Quarterly
$8.39M
Revenue by segment
Fulgent · $66M total across 1 segment · Q3 2023
- Core Revenue$66M+17.9%100.0%
Forward guidance
Fulgent Genetics will provide a formal update on its guidance regarding certain financial measures during its investment community conference call to shortly follow the issuance of this press release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-2.5%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.3%
Avg return
30 days after
37%
15 / 41 earnings
Positive
+38.3%
Q3 2019
Best reaction
-38.1%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.0% | -1.8% | +19.2% | |
| Q4 2025 | -38.1% | -43.5% | -37.0% | |
| Q3 2025 | +18.3% | +30.3% | +24.6% | |
| Q1 2025 | +18.7% | +8.1% | +20.1% | |
| Q4 2024 | -1.5% | +6.1% | +8.7% | |
| Q3 2024 | -9.0% | -16.3% | -8.8% | |
| Q2 2024 | +0.4% | -0.3% | -4.3% | |
| Q1 2024 | +1.2% | +0.1% | -2.8% | |
| Q4 2023 | -11.5% | -6.8% | -14.8% | |
| Q3 2023 | +14.0% | +11.1% | +15.5% | |
| Q2 2023 | -15.4% | -18.1% | -18.6% | |
| Q1 2023 | +16.1% | +23.4% | +41.4% | |
| Q4 2022 | -2.5% | +3.3% | -9.1% | |
| Q3 2022 | -8.6% | +3.3% | -2.4% | |
| Q2 2022 | -4.9% | -20.4% | -33.9% | |
| Q1 2022 | +4.4% | -4.1% | -1.6% | |
| Q4 2021 | -1.3% | +0.1% | -2.1% | |
| Q3 2021 | -1.1% | +10.5% | +4.3% | |
| Q2 2021 | -8.0% | -10.9% | -15.2% | |
| Q1 2021 | +3.9% | -2.5% | +2.6% | |
| Q4 2020 | -0.5% | +18.1% | +8.3% | |
| Q3 2020 | -17.0% | +6.9% | +20.0% | |
| Q2 2020 | +27.2% | +26.1% | +13.2% | |
| Q1 2020 | -21.0% | +3.9% | +10.3% | |
| Q4 2019 | -32.3% | -42.6% | -29.1% | |
| Q3 2019 | +38.3% | +68.1% | +26.0% | |
| Q2 2019 | +31.9% | +45.4% | +46.7% | |
| Q1 2019 | -15.8% | -16.5% | -11.3% | |
| Q4 2018 | +9.6% | +7.6% | +29.3% | |
| Q3 2018 | +6.9% | +12.3% | +2.8% | |
| Q2 2018 | -0.8% | -4.9% | -17.9% | |
| Q1 2018 | -0.3% | -2.3% | -4.9% | |
| Q4 2017 | -9.1% | -20.9% | -15.6% | |
| Q3 2017 | +0.4% | -4.0% | +0.9% | |
| Q2 2017 | -15.6% | -9.9% | -16.4% | |
| Q1 2016 | -31.1% | -30.0% | -53.4% | |
| Q1 2017 | -33.1% | -29.4% | -53.9% | |
| Q2 2016 | -3.8% | -9.0% | -7.5% | |
| Q4 2016 | +1.1% | -4.2% | -2.9% | |
| Q4 2015 | -1.6% | -1.7% | +8.2% | |
| Q3 2016 | -3.1% | -4.1% | +9.5% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro